CAMBRIDGE, Mass. - Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company with a market capitalization of $59.31 million, has entered into a clinical supply agreement with Regeneron ...

Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase ...

A research team affiliated with UNIST has unveiled an innovative technology to eliminate drug-resistant cancer cells using ...

Living with lymphoma for 15 years, I developed a concerning rash post-vacation, which led to a leukocytoclastic vasculitis ...

Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter ...

Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...

Becky Kamowitz was appointed executive director of The Skin Cancer Foundation in January 2025. She talks about the ...

Researchers Shed Light on How to Predict Which Skin Cancer Patients Are Most Likely to Respond to Immunotherapy Jan. 8, 2025 — An international team of UK and US scientists discovered that the ...

Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out as a therapy for an uncommon skin cancer called cutaneous squamous cell carcinoma (CSCC), but Sanofi and Regeneron are ...

Medicare covers inpatient and outpatient care for skin cancer. People with Original Medicare parts A and B or Medicare Advantage plans can expect extensive coverage, but they will likely have out ...

The stage of melanoma skin cancer tells you how thick it is and how far it has spread. Doctors use different systems to stage melanoma. These include the TNM system and number staging system. The ...

Although long considered a disease of aging, certain cancers are turning up more often in younger women, according to a new report. By Roni Caryn Rabin More Americans are surviving cancer ...